The Therapeutic Efficacy of the Moisturizer APDDR-0801 for Patients with Atopic Dermatitis.
- Author:
Juhee PARK
1
;
Kwang Hoon LEE
;
Jin Wou KIM
;
Young Suck RO
;
Cheon Wook PARK
;
Won Seok PARK
;
Hyun Ju KOH
;
Jeong Hwan KIM
;
Seong Jun SEO
Author Information
1. Department of Dermatology, Chung-Ang University College of Medicine, Seoul, Korea. drseo@hanafos.com
- Publication Type:Original Article
- Keywords:
Atopic dermatitis;
Ceramide;
Moisturizer;
Physiologic lipid granules;
Skin barrier
- MeSH:
Cytokines;
Dermatitis, Atopic;
Eczema;
Humans;
Pruritus;
Research Personnel;
Skin;
Sleep Initiation and Maintenance Disorders;
Stress, Psychological;
Treatment Outcome
- From:Korean Journal of Dermatology
2010;48(2):93-100
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: The patients with atopic dermatitis (AD) show a defective barrier function of the skin and symptoms such as xerosis, pruritus and erythematous lesions with increased transepidermal water loss (TEWL). The choice of topical moisturizer is very significant for AD patients because these symptoms could be relieved by a local moisturizing agent that strengthens the epidermal barrier function. OBJECTIVE: This study was performed to evaluate the effects of the moisturizer APDDR-0801, which contains physiologic lipid granules (DermaON(R)), for relieving the symptoms associated with AD. METHODS: 128 patients (17.8+/-12.1 years) who were suffering from mild to moderate AD topically applied the test moisturizer twice daily for up to 4 weeks. The treatment efficacy was evaluated by the investigator global assessment (IGA) score, the eczema area and severity index (EASI) score, the transepidermal water loss (TEWL), the visual analogue scale (VAS) for pruritus and sleep disturbance, and the level of inflammatory cytokines in the horny layer of the flexural areas. RESULTS: The test moisturizer was well-tolerated and 58.6% of the patients achieved clinical improvements (over moderate) after the application of the test moisturizer for 4 weeks. The significant relief of AD symptoms was observed from 2 week to 4 week in a time-dependent manner. Significant improvements in the signs and symptoms of AD were observed at 4 week, such as the EASI score (37.8% improvement), the TEWL (20.3% improvement in the antecubital fossa lesion), the VAS score for pruritus (26.2% improvement), and VAS score for insomnia (39.7% improvement). CONCLUSION: The moisturizer APDDR-0801 (Atobarrier Cream(R), which contains physiologic lipid granules, effectively relieved the symptoms associated with AD.
